Hyaluronic Viscosupplementation Market

Global Hyaluronic Viscosupplementation Market Snapshot

The global hyaluronic viscosupplementation market was valued at USD 2.3 Billion in 2022 and is expected to reach USD 4.0 Billion by 2033.

The three injection knee hyaluronic acid injections with around 49.1% in terms of value share, has topped the global Market within the product category in 2022 and is expected to grow at a CAGR of close to 5.2% over the forecast period (2023 to 2033)

Market Outlook:

Data Points	Market Insights
Market Value 2022	USD 2.3 Billion
Market Value 2023	USD 2.4 Billion
Market Value 2033	USD 4.0 Billion
CAGR 2023 to 2033	5.2%
Market Share of Top 5 Countries	73.2%
Key Market Players	Anika Therapeutics Inc.; Zimmer Biomet; Sanofi S.A.; LG Chem; Chugai Pharmaceutical Co.; Ltd.; Meiji Seika Pharma co. ltd; Ferring B.V.; Hanmi Pharm.Co.;Ltd.; Anika Therapeutics; Inc.; Fidia Farmaceutici s.p.a.; Bioventus LLC; OrthogenRx; Seikagaku Corporation; Bioiberica S.A.U.; APTISSEN; Hangzhou Singclean Medical Products Co.;Ltd; Maxigen Biotech Inc.; TRB Chemedica International SA; Yuria-Pharm LLC; Haohai Biological Technology; and Chroma Pharma

The injection of exogenous hyaluronic acid into diarthrodial joints restores synovial fluid characteristics, generating mechanical, analgesic, anti-inflammatory, and chondroprotective benefits. Hyaluronic acid is a polymer with a high viscosity and spatial structure. Rapid rehabilitation using hyaluronic acid filler offers relief from knee osteoarthritis, benefiting rheumatologists, rehabilitation providers, and primary care providers.

• According to EClinicalMedicine 2020, about 654 Billion people (40 years and older) globally have knee osteoarthritis, with a global incidence of 203 per 10,000 person-years.

Sales Analysis of Hyaluronic Viscosupplementation Market from 2012 to 2022 Vs Market Outlook for 2023 to 2033

The global market for hyaluronic viscosupplementation was around 24.4% of the overall USD 9.56 Billion of the global hyaluronic acid based products market in 2022.

Knee osteoarthritis is a chronic degenerative condition that affects the structure of the joints and causes inflammation, leading to joint discomfort and functional restrictions. Significant population globally suffers from osteoarthritis, a multifactorial origin joint disease, with high prevalence in adults.

• According to British Medical Journal 2022, Over 560 Million individuals worldwide suffer from knee osteoarthritis, making it the most common cause of impairment among older adults.
• The article in Revista Brasileira de Ortopedia 2015, around 40% of individuals over 65 age suffer from knee or hip symptoms.

Because of its low allergic reaction rate, simplicity of injection, speedy recovery, repeatability, and quick effects, hyaluronic acid filler has gained popularity. Hyaluronic acid injections into the joints are another common procedure, particularly for individuals with osteoarthritis of the knees.

In light of doctors' general reluctance to provide repeated injection of intra-articular corticosteroid injections, hyaluronic acid injection as a non-surgical therapeutic option have gained large popularity.

Owed to the above factors, the global market is projected to grow at CAGR of 5.2% in forecasted period.

What are the Key Opportunities for the Hyaluronic Viscosupplementation Manufacturers?

Viscosupplementation offers a structural benefit in knee osteoarthritis treatment, with improved visual appearance and increased cartilage volume. One year after treatment, joint surface reconstitutes, with reduced loss of joint space. This results in a cost-effectiveness relationship and potential delay in total knee arthroplasty.

First-line therapy for OA focuses on joint preservation and alleviating symptoms. Intra-articular hyaluronic acid injections (IAHA) are a promising nonsurgical treatment, particularly for mild-to-moderate OA and severe OA with comorbidities.

IAHA, a nonsurgical treatment modality, has gained popularity in managing knee OA, despite the lack of established disease-modifying treatments. Surgical methods for total knee replacement (TKR) are successful, although they have a risk-benefit ratio. Although intra-articular hyaluronic acid (IAHA) therapy or viscosupplementation have grown in recognition, there isn't enough solid research to back up their efficacy and safety.

IAHA gives patients with knee OA a little clinical benefit without safety issues, whereas viscosupplementation has a substantial benefit-to-risk ratio and speeds up TKR. IAHA improves knee OA by allowing lubrication, shock absorption, and re-establishing joint homeostasis through induction of endogenous HA production. It reduces analgesic usage to half and leads to a 40-month improvement in pain and joint function.

Price and synthesis of HA products vary, with some made synthetically through biotechnology, while others are derived from animals. These differences impact the healthcare system's economic impact. Stabilized hyaluronic acid, a new generation of HA preparations, offers a long half-life and high density, reducing injections and puncture risk in osteoarthritis treatment.

Viscosupplementation saves money in the long run by postponing surgery for severe pain, allowing therapeutic prosthesis installation, and enhancing the patient's quality of life.

What are the Factors Restraining the Demand for the Hyaluronic Viscosupplementation?

National and international guidelines discourage intra-articular hyaluronic acid derivatives. In countries like England, viscosupplementation is given low NHS funding priority due to the Institute's recommendation. HA injections in the knees are frequently associated with poor tolerance and failure rates, with anteromedial injections exhibiting up to 30% local reaction rates.

The efficacy of viscosupplementation is being questioned, which might be attributed to improper usage or a poorly fitted patient OA profile. A qualified expert is required for HA injection, which is difficult in a non-swollen joint. Some of research published claim hyaluronic viscosupplementation to be ineffective in osteoarthritis, these factors act as restraints for demand of hyaluronic viscosupplements.

Country-wise Insights

Why is USA Prominent Market for Hyaluronic Viscosupplementation in North America Region?

The USA occupies 50.0% of market share in 2022 globally. As per British Medical Journal (BMJ-Clinical research ed.) 2022, Medicare, and commercial insurance companies increased viscosupplementation coverage, with hyaluronic acid injections becoming first-line treatment for knee osteoarthritis.

• Medicare data shows USD287 Million in 2012, USD325 Million in 2018 was spent on treating joint infections after viscosupplementation injections.

This makes USA prominent market for hyaluronic viscosupplementation in North America.

What Makes Japan a Highly Lucrative Market for Hyaluronic Viscosupplementation?

Japan expenditure on hyaluronic viscosupplementation in 2022 was USD 198.4 Million.

• As per research article published in British Medical Journal, musculoskeletal disorders 2021-2022, Over 60% of adults in Japan suffer from radiographic knee OA, with 26% having symptomatic knee OA.

OA education, weight management, self-management, and exercise are crucial for improving knee OA. However, few patients are willing to undergo surgery, especially in Japan. Surgeons may delay surgery for elderly or unwilling patients, and there is a disconnect between physicians and patients. Improved communication between physicians and patients is needed to better understand the potential benefits of surgery. This makes Japan a Lucrative market for hyaluronic viscosupplementation market.

What Makes the China a Large Market for Hyaluronic Viscosupplementation?

In 2022, the China held a significant share in the East Asia market and contributed around USD 157.8 Million. China faces a significant burden of knee osteoarthritis, affecting 250 million people worldwide and causing disability.

• As per International Journal of Environmental Research and Public Health 2021, The disease burden is significant, with 249,000 knee arthroplasty cases in 2018, costing USD 1.79 Billion.

With a large population, more patients may require rehabilitation treatment and replacement, posing a significant public health burden for China. This makes China a large market for hyaluronic viscosupplements.

Category-wise Insights

Which Product is Predicted to Expand Rapidly Between 2023 and 2033?

By product, three injection knee hyaluronic acid injections held 49.1% market share in world in 2022.

• According to study published on Musculoskeletal Disorders 2017 in BioMed Central Ltd (BMC), Hyaluronic acid injections showed the greatest improvement in pain relief for knee OA patients with 2 to 4 injections compared to IA-Saline.

These injections were generally safe and showed a significant improvement in pain only at 6 months. However, more than or 5 injections were associated with a higher risk of treatment-related adverse events. Thus, demand for three injection knee hyaluronic acid injections are predicted to expand rapidly between 2023 and 2033.

Why Molecular Weight is Preferred Prominently in Hyaluronic Viscosupplementation?

The market value of high molecular weight hyaluronic viscosupplementation is USD 1.6 Billion, representing a sizable 68.8% market share in 2022. Hyaluronic acid is a high molecular weight polysaccharide used in various applications. The topic of molecular weight and hyaluronic acid's protective physicochemical functions remains controversial.

Most studies show a direct correlation between molecular weight and its effects on synoviocytes. However, some authors believe in vivo effects may differ due to excessive molecular size, preventing its ability to move from intra-articular to intercellular environments. The relationship between molecular weight and analgesia is evident in both in vitro and in vivo results, with products with molecular weight between 0.5 and 1 x 106 Da showing the best in vivo effects. Hence, high molecular weight hyaluronic viscosupplementation is preferred prominently.

Which Body Part will Garner Significant Value Share by 2033?

By body part, the knee accounted for the prominent share in the global hyaluronic viscosupplementation market, with a revenue share of 85.2% in 2022. This segment is expected to continue holding prominent market share by the end of forecast period.

• As per Clinical and Experimental Rheumatology 2005, Results show hyaluronic acid injections in knees, hips, shoulders, ankles, elbows, and other joints effectively treat osteoarthritic joints.

Viscosupplementation is an outpatient procedure for knees, with application method well established. Quantity and frequency depend on product characteristics and professional experience. Viscosupplementation in knee osteoarthritis has been observed to increase cartilage volume, with biopsies showing better matrix quality and increased chondrocyte density. This treatment may present a cost-effectiveness relationship, potentially reducing joint space loss.

Which End User is Benefiting the Global Market?

The ambulatory surgical centers have a considerable presence in the hyaluronic viscosupplementation market, accounting for 31.7% value share in 2022, and exhibiting a high CAGR of 5.5% over the forecast period.

Pseudosepsis cases submitted to the FDA, including those involving injections of non-cross-linked hyaluronic acid, necessitate rehabilitative therapy and anti-inflammatory medications. Ambulatory surgical centers offer expert guidance and 24/7 care, benefiting end users in the hyaluronic viscosupplementation market.

Competitive Landscape

Collaborations and collaborations among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten hyaluronic viscosupplementation. Collaboration in research, development, and commercialization can lead to market expansion and the creation of new applications. Numerous large firms compete in the field of hyaluronic viscosupplementation. Among the well-known players in this field are:

• In September 2021, Bioventus, Inc. has acquired CartiHeal Ltd. with a USD 50 Billion escrow payment, demonstrating its intent to acquire the proprietary Agili-C implant for joint cartilage lesions. CartiHeal's Agili-C was granted FDA Breakthrough Device Designation in 2012.
• In December 2021, Avanos Medical has acquired OrthogenRx, Inc., a leading provider of viscosupplementation therapies for knee osteoarthritis (OA) pain, for USD 160 Billion. The acquisition includes USD 130 Billion in cash and USD 30 Billion in contingent cash consideration. HA therapy offers a USD 1 billion commercial opportunity in the US, complementing Avanos' COOLIEF* Cooled Radiofrequency pain treatment portfolio.

Similarly, recent developments related to the company’s manufacturing the hyaluronic viscosupplementation injections have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope as Per Hyaluronic Viscosupplementation Industry Analysis

Attributes	Details
Forecast Period	2023 to 2033
Historical Data Available for	2012 to 2022
Market Analysis	USD Million for Value, Units for Volume
Key Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA)
Key Countries Covered	USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, United Kingdom, Spain, BENELUX, Russia, Nordics, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Israel, Northern Africa and South Africa.
Key Market Segments Covered	Product, Body Part, Molecular Weight, Indication, End User, and Region
Key Companies Profiled	Anika Therapeutics Inc.; Zimmer Biomet; Sanofi S.A.; LG Chem; Chugai Pharmaceutical Co., Ltd.; Meiji Seika Pharma co. ltd; Ferring B.V.; Hanmi Pharm.Co.,Ltd.; Anika Therapeutics, Inc.; Fidia Farmaceutici s.p.a.; Bioventus LLC; OrthogenRx; Seikagaku Corporation; Bioiberica S.A.U.; APTISSEN; Hangzhou Singclean Medical Products Co.,Ltd; Maxigen Biotech Inc.; TRB Chemedica International SA; Yuria-Pharm LLC; Haohai Biological Technology; Chroma Pharma
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing	Available upon Request

Key Market Segments Covered in the Hyaluronic Viscosupplementation Industry Research

By Product:

• Single Injection Knee Hyaluronic Acid Injections
• Three Injection Knee Hyaluronic Acid Injections
• Five Injection Knee Hyaluronic Acid Injections
• Next Generation (Steroid Combination)

By Body Parts:

• Knee
• Hip
• Shoulder
• Small Joints
• Others

By Molecular Weight:

• High Molecular Weight
• Medium Molecular Weight
• Low Molecular Weight

By Indication:

• Knee Osteoarthritis
• Tendinopathies
• Shoulder Arthritis
• Hip Osteoarthritis
• Frozen Shoulder
• Ligament Injury
• Post-Arthroscopy
• Others

By End User:

• Hospitals
• Ambulatory Surgical Centers
• Orthopaedic Clinics
• Retail Pharmacies
• Online Sales

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Frequently Asked Questions

What is the Current Valuation of the Hyaluronic Viscosupplementation Market?

The market registers USD 2.4 billion in revenue in 2023.

What is the Estimated Market Size Envisioned by 2033?

The global market revenue is projected to exceed USD 4.0 billion by 2033.

What CAGR is Foreseen for the Market in the Upcoming Decade?

Sales of hyaluronic viscosupplementation is expected to record a 5.2% CAGR through 2033.

Which Country Underscores Substantial Revenue Prospects?

Hyaluronic viscosupplementation boasts substantial revenue prospects in Japan.

What was the Market's Past Record like?

The market secured USD 2.3 billion revenue in 2022.